Daihan Pharmaceutical Co.Ltd Total Assets
Daihan Pharmaceutical Co.Ltd total assets. Based on the latest financial reports, Daihan Pharmaceutical Co.Ltd (023910) holds total assets worth ₩344.02 Billion KRW (≈ $233.14 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 023910 market cap for the company's overall valuation and market capitalisation.
Total Assets of Daihan Pharmaceutical Co.Ltd (2014–2024)
Total assets of Daihan Pharmaceutical Co.Ltd from 2014 to 2024. This chart illustrates how Daihan Pharmaceutical Co.Ltd's total assets have evolved over time, based on quarterly financial data. See today's stock price for Daihan Pharmaceutical Co.Ltd for real-time trading data and today's change.
Daihan Pharmaceutical Co.Ltd - Asset Composition Analysis
Daihan Pharmaceutical Co.Ltd Total Assets Breakdown (December 2024)
Daihan Pharmaceutical Co.Ltd total assets breakdown as of December 2024. Daihan Pharmaceutical Co.Ltd's total assets of ₩344.02 Billion consist of 42.3% current assets and 57.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩61.25 Billion | 18.9% |
| Accounts Receivable | ₩31.23 Billion | 9.6% |
| Inventory | ₩26.73 Billion | 8.2% |
| Property, Plant & Equipment | ₩134.44 Billion | 41.4% |
| Intangible Assets | ₩397.01 Million | 0.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Daihan Pharmaceutical Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Daihan Pharmaceutical Co.Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Daihan Pharmaceutical Co.Ltd's current assets represent 42.3% of total assets in 2024, a decrease from 47.7% in 2014.
- Cash Position: Cash and equivalents constituted 18.9% of total assets in 2024, up from 2.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 41.4% of total assets.
Daihan Pharmaceutical Co.Ltd Competitors by Total Assets
Key competitors of Daihan Pharmaceutical Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Daihan Pharmaceutical Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.55 | 3.45 | 3.10 |
| Quick Ratio | 2.78 | 2.76 | 2.50 |
| Cash Ratio | 0.00 | 1.78 | 0.00 |
| Working Capital | ₩111.25 Billion | ₩94.11 Billion | ₩82.46 Billion |
Daihan Pharmaceutical Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Daihan Pharmaceutical Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.59 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 10.2% |
| Total Assets | ₩324.41 Billion |
| Market Capitalization | $98.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values Daihan Pharmaceutical Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Daihan Pharmaceutical Co.Ltd's assets grew by 10.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Daihan Pharmaceutical Co.Ltd (2014–2024)
The table below shows the annual total assets of Daihan Pharmaceutical Co.Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩324.41 Billion ≈ $219.85 Million |
+10.25% |
| 2023-12-31 | ₩294.25 Billion ≈ $199.41 Million |
+6.24% |
| 2022-12-31 | ₩276.98 Billion ≈ $187.71 Million |
+1.63% |
| 2021-12-31 | ₩272.54 Billion ≈ $184.70 Million |
+7.69% |
| 2020-12-31 | ₩253.09 Billion ≈ $171.52 Million |
+2.53% |
| 2019-12-31 | ₩246.85 Billion ≈ $167.29 Million |
+5.15% |
| 2018-12-31 | ₩234.75 Billion ≈ $159.09 Million |
+27.30% |
| 2017-12-31 | ₩184.40 Billion ≈ $124.97 Million |
+15.03% |
| 2016-12-31 | ₩160.31 Billion ≈ $108.64 Million |
+15.47% |
| 2015-12-31 | ₩138.83 Billion ≈ $94.08 Million |
+5.48% |
| 2014-12-31 | ₩131.61 Billion ≈ $89.19 Million |
-- |
About Daihan Pharmaceutical Co.Ltd
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.